Recruiting

Tumor Profiling

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT03039439

Conditions

Parathyroid Gland Adenoma

Parathyroid Gland Atypical Adenoma

Parathyroid Gland Carcinoma

Primary Hyperparathyroidism

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Laboratory Biomarker Analysis

Study Details

Brief summary:

This trial studies molecular and immunohistochemical profiling of tumors in patients with parathyroid tumors. Studying molecular and immunohistochemical profiling of tumors may help doctors avoid inconsistencies in diagnosis, unnecessary or incomplete surgery, surgical morbidity, psychological stress, and inadequate follow up.

Conditions

Parathyroid Gland Adenoma

Parathyroid Gland Atypical Adenoma

Parathyroid Gland Carcinoma

Primary Hyperparathyroidism

Study ID

NCT03039439

Start date

Nov 24, 2015

Status verified date

May, 2026

Completion date

Nov 30, 2028

Anticipated

Primary completion date

Nov 30, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • The patient cohort for this study consists of all patients within the prospectively maintained parathyroid database within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center (MDACC) or from collaborating sites, with tissue or blood available from 1968-2015, previously consented for the use of the tissue for research purposes (via Protocols LAB 08-0034, PA11-0695 and LAB03-0320 or the appropriate external mechanism for collaborating sites).
  • All patients with a known diagnoses of primary hyperparathyroidism (PHPT) operated/treated in the Department of Surgical Oncology of MDACC or at a collaborating site. Patients that have provided consent for the use of the tissue or blood for research purposes will then be considered for our study (via Protocol LAB03-0320 and LAB 08-0034 or the appropriate external mechanism for collaborating sites).
  • All consented patients with known diagnoses of PHPT with a histopathological diagnosis of: parathyroid carcinoma, atypical parathyroid neoplasm or parathyroid adenoma. There will be no restrictions on age, gender, or ethnicity.
  • Selected patients obtained through outside collaboration who meet the selection criteria for tissue availability and diagnostic suitability for inclusion in the study.

Exclusion Criteria:

  • Patients without tissue available for analysis.

Study Design

Enrollment

310 participants

Anticipated

Interventions and Outcome Measures

Arms

Ancillary-Correlative (laboratory biomarker analysis)

Previously collected tumor tissue and blood samples are analyzed via immunohistochemical profiling for identifying potential genes showing molecular aberrations as other types of cancer.

Interventions

Biospecimen Collection

Previously collected tumor tissue and blood samples

Laboratory Biomarker Analysis

Correlative studies

Primary outcome measure

  • Biomarker levels [ Time Frame: Up to 4 years ]
  • Identify the potential genes that can be used in patients with parathyroid tumors for diagnostic purposes [ Time Frame: Up to 4 years ]

Central Contacts and Locations

Central contacts

Nancy D. Perrier

713-792-6940nperrier@mdanderson.org

Locations

M D Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Nancy Perrier

713-745-2168

Principal Investigator:

Nancy Perrier

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

May 22, 2026

Last verified

May, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-05-22.